Study: Most new drugs subject to PREA requirements have ongoing postmarketing studies
Regulatory NewsJeff Craven
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesClinical TrialsPediatric productsPharmaceuticalsUnited StatesUS Food and Drug Administration (FDA)